SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-065459
Filing Date
2023-03-09
Accepted
2023-03-09 09:02:01
Documents
17
Period of Report
2023-03-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d463641d8k.htm   iXBRL 8-K 36165
2 EX-1.1 d463641dex11.htm EX-1.1 164726
3 EX-5.1 d463641dex51.htm EX-5.1 8373
4 EX-99.1 d463641dex991.htm EX-99.1 7839
5 EX-99.2 d463641dex992.htm EX-99.2 8390
9 GRAPHIC g463641g0308141716266.jpg GRAPHIC 2668
  Complete submission text file 0001193125-23-065459.txt   410849

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA bbio-20230307.xsd EX-101.SCH 2844
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20230307_lab.xml EX-101.LAB 17994
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20230307_pre.xml EX-101.PRE 11257
11 EXTRACTED XBRL INSTANCE DOCUMENT d463641d8k_htm.xml XML 3348
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 23718362
SIC: 2834 Pharmaceutical Preparations